Published by: Feedback Admin on 24 Apr 2015.
Share price movement
The Board of Feedback plc notes the rise in the Company’s share price over the last few trading days. The Board is unaware of any specific reason that would lead to such a movement in the Company’s share price and the increase in trading volumes.The Company remains in active discussions with potential customers for its medical imaging software.
Published by: Feedback Admin on 22 Apr 2015.
IS this Beauty the next Advanced Oncotherapy? – That’s What I Heard at the Big UK Investor Show.
By Malcolm Stacey | ShareProphets | Wednesday 22 April 2015
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Hello Share Pickers. I told you I usually pick up some decent tips from the UK Investor Show which we were all treated to on Saturday. I’ve now had time to research a few of these diamonds and the first one I’ve bought is Feedback (FDBK).
This is one of those life science shares. And as I had so much luck with my 2015 tip Advanced Oncotherapy (AVO) – turning it into a five bagger- I thought this is an area which seems interesting.
Feedback comes from the bloke who first pointed me to Advanced, Alan Green. I always take notice of what he says because, despite an initial failure with Creightons (CRI) his tips – including Arm Holdings (ARM) and BT (BT.A) have both rattled ahead since I bought them two or three years ago.
Anyway, back to Feedback. This is a minnow of a company with a market cap of just £3 million. The shares are less than 2p now, but they’ve nearly doubled since the beginning of this month.
They’re running at a loss, but like all companies in this very exciting field, the share price is in the future.
You’ll know, if you’ve been unlucky enough to be in hospital lately, that modern doctors put a great deal of reliance on computers to tell what’s wrong with you and how to put you back on your feet. This company supplies the means of making medical images on the screen.
Don’t ask me for me details. I’m a medical simpleton. But look them up for yourself.
Any road up, the share has shot up lately, due to four big cancer institutions taking the software. They’re in Berlin, Tokyo, Cardiff and Reims. So wide-ranging interest there, then.
Because of the miniscule share valuation, I had to pay a 15% spread, despite pleading with my broker. Never mind, it’s easier for a 2p share to double than one of £6.
I’m now going to see what they all say about Feedback in the Punter’s Return
Published by: Feedback Admin on 20 Apr 2015.
Adoption of TexRAD research software
Feedback PLC is pleased to announce the adoption of its TexRAD research software by four further leading cancer research institutions.
- The Evangelische Lungenklinik Berlin (ELK)
ELK is an internationally recognised specialist hospital for diseases of the chest treating more than 18,000 patients annually. The sale of the TexRAD research software to the Radiology Department at ELK is our first sale into Germany. This installation will be used to evaluate lung cancer treatment outcomes, one of the leading causes of cancer mortality and a key area of interest for TexRAD.
- Velindre Cancer Centre, Cardiff, Wales, UK
This first sale in Wales is an important milestone in the development phase of TexRAD where the Company’s software is being used by clinical oncologists as a research tool in assessing tumour heterogeneity as a way of monitoring the progression and response of tumours to therapy.
- University of Tokyo, Department of Radiology at the Institute of Medical Science
Japan has one of the highest numbers of CT and MRI scanners per capita in the world. This leading research institute joins the Company’s growing list of adopters to use TexRAD software for research purposes.
- Centre Hospitalier Universitaire De Reims, Reims, France
This is the Company’s first major hospital site outside Paris, where it already has two prestigious sites as users. Here the Company will be providing a customised laptop solution (rather than the Company’s standard server-based solution) demonstrating its flexibility in meeting the specific requirements of clients.
These recent sales of TexRAD, together with others over the last two months with a combined sales value of over £100,000, are a further indication of the interest in TexRAD as a potentially valuable quantitative tool in cancer research. The revenue associated with these sales will be recognised over the life of the 12 month contracts in accordance with the Company’s revenue recognition accounting policy.
Tom Charlton, Director of Feedback plc, commented: “We are delighted by the interest from leading centres of oncology research in using our TexRAD texture analysis software”
Published by: Feedback Admin on 13 Apr 2015.
Collaboration with the Oxford Stone Group, University of Oxford & Oxford University Hospital NHS Trust, Oxford, UK
Feedback plc is pleased to announce that it has signed a research agreement with the Oxford Stone Group at the University of Oxford & Oxford University Hospital NHS Trust in Oxford, UK to investigate the potential clinical application of Feedback’s TexRAD texture analysis software on CT image data of patients with kidney stones.
The research collaboration will be led by Mr Ben Turney (Bernard Senior Clinical Researcher in Urology at the University of Oxford and Honorary Consultant Urological Surgeon) and Mr Daniel Stevens (Academic Clinical Fellow in Urology at the University of Oxford). As part of the Oxford Stone Group, Mr Turney is developing an international reputation for innovative and original research into the causes and treatment of urological stone disease.
The field of kidney stone management includes all forms of detection diagnosis and treatment of stones. In the UK, an estimated 85,000 patients attend hospital with kidney stones each year. Treatment options include Shock Wave Lithotripsy (an ultrasound based shock wave technique to break up the stones after which the tiny pieces of stone pass out of the body in the urine) or endoscopic surgery to fragment the stones using lasers. Around 40,000 treatments for kidney stones are performed in the UK each year. Stones commonly affect people between the ages of 20 and 60 and consequently the combined direct costs of treatment and indirect costs in terms of days off work are very considerable.
The majority of stone patients undergo CT scans as part of their diagnostic evaluation. TexRad based CT texture analysis of the stones in these scans might improve several aspects of stone management:
- Diagnostic accuracyOften there are other features on scans that can be confused with kidney stones (mimics such as phleboliths, calcification in arteries and calcified nodes). Image analysis might increase the diagnostic confidence and prevent unnecessary costly investigation and treatments.
- Prediction of response to different treatmentsSome stones respond well to shock wave lithotripsy while others are resistant. Image analysis might allow accurate triaging of patients to the correct treatment first time. This would have clear cost benefits to clinical services.
- Determination of stone compositionImage analysis might allow correlation with stone composition. This would be important in advising the patient about prevention strategiesPotentially, these benefits could be extracted from images that are routinely acquired for patients with kidney stones.Identifying which patients will benefit from lithotripsy would help to streamline treatment pathways and better allow clinicians to advise patients in choosing the right option for them. Similarly, using a non-invasive tool to better evaluate the composition of the stone facilitates personalised advice.Initially Mr Turney and his team will be undertaking a pilot study of 100 patients with kidney stones on KUB CT, with four key objectives:
- TexRAD analysis of the stone on CT to look for any variation in stone characteristics. What is the heterogeneity between different stones and within individual stones?
- Evaluate the relationship between the TexRad score and clinical outcome from shock wave lithotripsy in an independent cohort of patients.
- Correlate TexRad parameters and stone composition determined by the gold standard FTIR analysis.
- Characterise the TexRad differences between stones and other mimics.
Feedback plc is focused on establishing the use of TexRAD in clinical practice. To achieve this, Feedback plc has established a strong customer base and research collaborations with key opinion leaders at world class imaging research centres and hospitals around the world. The research collaboration with the University of Oxford & Oxford University Hospital NHS Trust is another such example.
Mr Ben Turney, a leading authority on stone disease in the UK, commented: “The prevalence of kidney stone disease is increasing globally. There is an important need to continue to develop and improve technology that will support personalised care in the management of patients with kidney stones. Feedback’s TexRAD software offers the potential for important advances in this field. TexRAD captures key heterogeneity information, which will be crucial in understanding stone characteristics in a non-invasive and cost-effective manner from routinely acquired diagnostic CT images. This will potentially assist in more accurate patient risk-stratification and treatment decision choices.”
Dr. Balaji Ganeshan, Chief Scientist & New Business Officer, TexRAD Ltd & CCI (both part of Feedback plc) commented: “Mr Turney is a leading stone expert in the UK and we are delighted that he will be leading the research team working with our TexRAD software. The Oxford Stone Group as part of the University of Oxford and Oxford University Hospital NHS Trust is a leading research centre in the United Kingdom and we are delighted to be working with them and enhancing our TexRAD research collaborator base with the addition of another key site and opinion leader in the region.”
For further information contact:
Tel: 01954 718072
Simon Barrell / Trevor Brown / Tom Charlton
Sanlam Securities UK (Nominated Adviser and Joint Broker)
Simon Clements / Virginia Bull
Tel: 020 7628 2200
Peterhouse Corporate Finance Ltd (Joint Broker)
Tel: 020 7469 0936
Lucy Williams / Duncan Vasey
Published by: Feedback Admin on 27 Feb 2015.
TexRAD’s Dr Ganeshan presenting at European Congress of Radiology
Feedback plc will be attending the European Congress of Radiology – the scientific assembly and annual meeting of the European Society of Radiology from 4th March to 8th March 2015 at the Austria Center in Vienna, Austria.
Dr. Balaji Ganeshan, Chief scientist & New Business Officer, TexRAD Limited & Cambridge Computed Imaging Limited and other collaborators will be presenting a number of TexRAD related papers particularly in breast (novel quantitative radiomic analysis to identify high-risk breast cancer phenotype on PET-CT), colorectal (pre-operative CT texture analysis predicts outcome in patients with colorectal liver metastases post liver resection and MR texture analysis was a better marker of response to Neoadjuvant Chemotherapy in rectal cancer patients on 3-T MR than diffusion and perfusion parameters) and lung (multi-parametric PET-CT correlates with hypoxia, angiogenesis and ALK expression) cancers at ECR.
For further information contact:
Feedback plc 01954 718072
Simon Barrell/Trevor Brown/Tom Charlton
Sanlam Securities UK – Simon Clements / Virginia Bull
Tel: 020 7628 220
Notes for Editors:
TexRAD (is a novel sophisticated imaging risk stratification research tool that analyses the textures in existing radiological scans. This research software application analyses textures, detecting and measuring tumour heterogeneity (complexity) from these images, revealing more information from medical images than it is currently possible to see with the naked eye. Research to date has shown that TexRAD could potentially assist the clinician (as an ‘Imaging-Biomarker’) in confident decision-making: assessing the prognosis, disease-severity (e.g. risk of metastases) and response evaluation of patients with cancer. Currently TexRAD research has shown great potential in many different oncological sites, including, colorectal, breast, lung, prostate, oesophageal, head & neck, lymphoma, liver and renal cancers and could potentially be employed as a heterogeneity assessing tool in the era of ‘Precision and Personalized Medicine’.TexRAD is manufactured under licence by the ISO 13485 certified company Cambridge Computed Imaging Ltd, a subsidiary of Feedback plc. More information is available on www.fbk.com and www.texrad.com